Company intelligence / Profile preview
Unicyte
Oberdorf, Switzerlandunicyte.ch ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Unicyte is developing proprietary stem cell and extracellular vesicle-based therapies targeting kidney, liver, metabolic, and oncological diseases, currently at phase 2 clinical stage for some programs, with preclinical and translational data supporting regenerative efficacy in diabetes, nephropathy, and oncology.
- Therapeutic areas
- EndocrinologyNephrologyGastroenterologyOncology
- Modalities
- Stem cell therapyExosome-based therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Fresenius Medical CareUniversity of Turin
Beyond the preview
Go deeper on Unicyte.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unicyte.